Cargando…

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma

Background: Targeted therapy has transformed the outcome for patients with metastatic renal cell carcinoma. Their efficacy and safety have also been demonstrated in brain metastatic RCC. Preclinical evidence suggests synergism of radiation and tyrosine kinase inhibitors. Consequently, several studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad, Zhao, Zhihong, Arooj, Sumbal, Liao, Guixiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390930/ https://www.ncbi.nlm.nih.gov/pubmed/32793497 http://dx.doi.org/10.3389/fonc.2020.01246

Ejemplares similares

Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2020)

Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review
por: Liao, Guixiang, et al.
Publicado: (2021)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2022)

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
por: Petrazzuolo, Adriana, et al.
Publicado: (2022)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases
por: Khan, Muhammad, et al.
Publicado: (2020)

Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors
por: Khan, Muhammad, et al.
Publicado: (2019)

Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
por: Liu, Jiayin, et al.
Publicado: (2023)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
por: Ma, Chunhua, et al.
Publicado: (2020)

The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs)
por: Ghafary, Ismail, et al.
Publicado: (2023)

Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
por: Khan, Muhammad, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
por: Arena, Claudia, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study
por: Zhuang, Hongqing, et al.
Publicado: (2020)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Metastatic renal cell carcinoma of the native kidney in a renal transplant recipient: Revisiting the era of tyrosine kinase inhibitors – Case report
por: Suso-Palau, Daniel, et al.
Publicado: (2022)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients
por: Du, Xiao-Jing, et al.
Publicado: (2018)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
por: Tamura, K., et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
por: Luo, Laihui, et al.
Publicado: (2022)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_diljk7nvv3qlsck4gdc4pc45kv